M

Maze Therapeutics

Clinical-stage biotech developing precision kidney therapies

Director Field Medical - Central

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • An advanced scientific degree (PharmD, PhD, MD, DO, or equivalent) is required.
  • A minimum of 7 years of Medical Affairs, Field Medical, Clinical Development, or related biopharmaceutical experience is required.
  • A demonstrated track record building key opinion leader relationships and leading peer-to-peer scientific exchange is required.
  • Demonstrated accountability for site engagement and clinical trial enrollment, not solely data presentation at sites, is required.
  • Deep scientific fluency and the credibility to hold a peer-level conversation with an academic specialist are required.
  • Willingness to travel approximately 60–70% within the assigned region is required.

Responsibilities

  • Lead compliant, peer-to-peer scientific exchange with thought leaders, physicians, renal pathologists, and PKU specialists, and build a durable regional key opinion leader map, including in a metabolic community where Maze is not yet known.
  • Provide accurate scientific education on AMKD, FSGS, CKD, and PKU, including APOL1 biology and SLC6A19 substrate reduction, and respond to unsolicited medical inquiries.
  • Represent Maze at major congresses, including ASN, NKF, and metabolic/PKU societies, and support advisory boards, scientific meetings, and patient advocacy partnerships.
  • Serve as the regional scientific partner to Maze’s trials, including HORIZON, MZE829, and MZE782, and act as the single point of contact for investigators and sites.
  • Shape site selection through feasibility input, and support site identification, investigator meetings, and start-up.
  • Own the field-side response to enrollment and retention barriers, driving compliant scientific solutions with Clinical Operations.
  • Support adoption of APOL1 genotyping and advance genotype-driven patient identification pathways for eligible patients to reach the trials.
  • Address trust and access barriers facing an AMKD population disproportionately of African ancestry as an enrollment lever.
  • Capture field insight on treatment patterns, unmet need, evidence gaps, and competitive intelligence on a consistent cadence, and translate it into recommendations that shape medical strategy, evidence generation, and launch readiness.
  • Carry the assigned territory personally as the senior regional scientific leader, and help recruit, mentor, and develop MSLs as the organization scales, growing into regional team leadership over the next 1–2 years.
  • Build communication channels across Maze for sharing information; influence senior management decisions through persuasive arguments; and respectfully address differing opinions to gain support for decisions.
  • Champion partnerships and connections across Maze, proactively address issues that could break down team relationships, and spotlight team and individual contributions in public forums.
  • Address gaps and leverage strengths to get results, maintain a steadying presence and clarify priorities during change, and anticipate and remove barriers that put functional or corporate goals at risk.
  • Remove barriers to staff development, empower staff to make their own decisions, stay current on industry trends, and keep direct reports prepared and responsive.

Desired Qualifications

  • Nephrology depth with existing relationships in the kidney community, and genuine willingness to build metabolic and PKU fluency.
  • Pre-commercial or first-launch biotechnology experience built without an established field infrastructure.
  • Experience with genotype-driven patient identification and diagnostic testing pathways.
  • Experience mentoring MSLs or leading congress and scientific-platform initiatives.

About the Company

Maze Therapeutics

Clinical-stage biotech developing precision kidney therapies

Maze Therapeutics is a clinical-stage biotechnology company that builds precision medicines for diseases with large unmet needs by using human genetics to copy protective genetic variants into small-molecule drugs. Its Compass platform maps genetic insights to therapeutic targets through variant functionalization, guiding drug discovery across research, preclinical, and clinical stages. Its lead program MZE829 targets APOL1-driven kidney disease, while MZE782 is in development for chronic kidney disease and phenylketonuria. Unlike many peers, Maze focuses on turning natural genetic protections into medicines and aims to develop and commercialize its own therapies.

Company size
51-200
Company stage
IPO
Headquarters
South San Francisco, CA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Maze Therapeutics

See more jobs